

FORM PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.: AME-06381

Serial No.: 09/982,464

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use Several Sheets If Necessary)Applicant: William D Huse *et al.*

(37 CFR § 1.98(b))

Filing Date: 10/18/2001

Group Art Unit: 1642

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	5,223,409	6/29/93	Ladner <i>et al.</i>			3/1/91
	2	5,225,539	10/25/91	Winter			10/25/91
	3	5,264,563	11/23/93	Huse			12/14/92
	4	5,403,484	4/4/95	Ladner <i>et al.</i>			1/26/93
	5	5,523,388	6/4/96	Huse			2/27/95
	6	5,585,089	12/17/96	Queen <i>et al.</i>			6/7/95
	7	5,693,762	12/2/97	Queen <i>et al.</i>			6/7/95
	8	5,723,323	3/3/98	Kauffman <i>et al.</i>			12/2/94
	9	5,814,476	9/29/98	Kauffman <i>et al.</i>			6/5/95
	10	5,817,483	10/6/98	Kauffman <i>et al.</i>			6/5/95
	11	5,824,514	10/20/98	Kauffman <i>et al.</i>			6/5/95
	12	5,871,974	2/16/99	Huse			12/2/94
	13	5,976,862	11/2/99	Kauffman <i>et al.</i>			6/5/95
	14	5,977,322	11/2/99	Marks <i>et al.</i>			6/13/96
	15	6,096,551	8/1/00	Barbas <i>et al.</i>			9/16/97
	16	6,312,693	11/6/01	Aruffo <i>et al.</i>			2/10/99

**FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS**

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
	17	0 451 216 B1	10/16/91	EPO				
	18	0 682 040 B1	11/15/95	EPO				
	19	0 939 127 A2	9/01/99	EPO				
	20	0 519 596 A1	5/12/92	EPO				
	21	WO 99/42075	26.08.99	PCT				
	22	2,125,240 A1	12/7/95	CA				

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

	23	Amit <i>et al.</i> , "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution," <i>Science</i> 233:747-753 (1986)
	24	Baca <i>et al.</i> , "Antibody humanization using monovalent phage display," <i>J. Biol Chem</i> 272:10678-84 (1997)
	25	Baca <i>et al.</i> , "Phage display of a catalytic antibody to optimize affinity for transition-state analog binding," <i>Proc Natl Acad Sci USA</i> 94:10063-10068 (1997)
	26	Chothia <i>et al.</i> , "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> 342:877-883 (1989)

Examiner:

Date Considered:

**EXAMINER:** Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: AME-06381	Serial No.: 09/982,464
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)				Applicant: William D Huse <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 10/18/2001	Group Art Unit: 1642
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
27	Chothia <i>et al.</i> , "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> 196:901-917 (1987)				
28	Durie <i>et al.</i> , "Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease," <i>J Clin Invest</i> 94:1333-1338 (1994)				
29	Foote and Winter, "Antibody framework residues affecting the conformation of the hypervariable loops," <i>J Mol Biol</i> 224:487-499 (1992)				
30	Foy <i>et al.</i> , "Immune Regulation by CD40 and its Ligand GP39," <i>Annu Rev Immunol</i> 14:591-617 (1996)				
31	Francisco <i>et al.</i> , "In Vivo Efficacy and Toxicity of a single-Chain Immunotoxin Targeted to CD40," <i>Blood</i> 89:4493-4500 (1997)				
32	Francisco <i>et al.</i> , "Activity of a single-Chain Immunotoxin that Selectively Kills Lymphoma and other B-Lineage Cells expressing the CD40 Antigen," <i>Cancer Res</i> 55:3099-3104 (1995)				
33	Glaser <i>et al.</i> , "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," <i>J. Immunology</i> 149:3903-3913 (1992)				
34	Harris & Bajorath, "Profiles for the analysis of immunoglobulin sequences: Comparison of V gene subgroups," <i>Prot Sci</i> 4:306-310 (1995)				
35	Herren <i>et al.</i> , "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <i>J Molecular Biology</i> 294:151-162 (1999)				
36	Huston <i>et al.</i> , "Antigen Recognition and Targeted Delivery by the Single-Chain Fv," <i>Cell Biophysics</i> , 22:189-224 (1993)				
37	Irving <i>et al.</i> , "Affinity maturation of recombinant antibodies using <i>E. coli</i> mutator cells," <i>Immunotechnology</i> 2:127-143 (1996)				
38	Jones <i>et al.</i> , "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> 321:522-525 (1986)				
39	Jönsson and Malmquist, "Real Time Biospecific Interaction Analysis," <i>Advances in Biosensors</i> , 2:291-336 (1992)				
40	Kabat <i>et al.</i> , <i>Sequences of protein of immunological interest.</i> , (5th Ed) Washington DC: United States Department of Health and Human Services (1991)				
41	Kabat <i>et al.</i> , "Unusual distributions of amino acids in complementarity determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody combining sites," <i>J. Biol. Chem.</i> 252, 6609-6616 (1977)				
42	Kristensson <i>et al.</i> , "Humanization of a murine antibody against cryptococcus neoformans polysaccharide using a novel approach," <i>Vaccines</i> 95, pp. 39-43 Cold Springs Harbor Laboratory Press, Cold Spring Harbor, NY (1995)				
43	Kunkel, "Rapid and Efficient site-specific mutagenesis without phenotypic selection," <i>Proc Natl. Acad Sci USA</i> 82:488-492 (1985)				
44	MacCallum <i>et al.</i> , "Antibody-antigen interactions: contact analysis and binding site topography," <i>J. Mol. Biol.</i> 262:732-745 (1996)				
45	Mach <i>et al.</i> , "Reduction of atherosclerosis in mice by inhibition of CD40 signalling," <i>Nature</i> 394:200-203 (1998)				
46	Padlan, "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," <i>Mol Immunol</i> 28:489-498 (1991)				
47	Padlan, "Anatomy of the antibody molecule," <i>Mol Immunol</i> 31:169-217 (1994)				
48	Plückthun and Skerra, "Expression of Functional Antibody Fv and Fab Fragments in <i>Escherichia coli</i> ," <i>Meth. Enzymol.</i> , 178:497-515 (1989)				
49	Rader <i>et al.</i> , "A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," <i>Proc Natl Acad Sci USA</i> 95:8910-8915 (1998)				
50	Riechmann <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature</i> 332:323-327 (1988)				
51	Rosok <i>et al.</i> , "A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab," <i>J Biol Chem</i> 271:22611-22618 (1996)				
52	Rudikoff <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity," <i>Proc Natl Acad Sci USA</i> 79:1979-1983 (1982)				
53	Schier <i>et al.</i> , "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," <i>J Mol Biol</i> 263:551-567 (1996)				
Examiner:				Date Considered:	
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

<b>FORM PTO-1449</b> (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: AME-06381	Serial No.: 09/982,464
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use Several Sheets If Necessary)				Applicant: William D Huse <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 10/18/2001	Group Art Unit: 1642
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	54	Schreiber & Fersht, "Energetics of protein-protein interactions: Analysis of the barnase-barstar interface by single mutations and double mutant cycles," <i>J Mol Biol</i> 248:478-486 (1995)			
	55	Singer <i>et al.</i> , "Optimal humanization of 1B4, an anti-CD 18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences," <i>J Immunol</i> 150:2844-2857 (1993)			
	56	Stamenkovic <i>et al.</i> , "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas," <i>EMBO J</i> 8(5): 1403-1410 (1989)			
	57	Studnicka <i>et al.</i> , "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity modulating residues," <i>Protein Eng</i> 7:805-814 (1994)			
	58				
	59	Thompson <i>et al.</i> , "Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity," <i>J Mol Biol</i> 256:77-88 (1996)			
	60	Uckun <i>et al.</i> , "Temporal Association of CD40 Antigen Expression with Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia as Well as B-Lineage Non-Hodgkin's Lymphoma Cells," <i>Blood</i> 76(12):2449-2456 (1990)			
	61	Watkins <i>et al.</i> , "Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries," <i>Anal Biochem</i> 256:169-177 (1998)			
	62	Watkins <i>et al.</i> , "Determination of the relative affinities of antibody fragments expressed in <i>Escherichia coli</i> by enzyme-linked immunosorbent assay," <i>Anal Biochem</i> 253:37-45 (1997)			
1	63	Wu <i>et al.</i> , "Stepwise in vitro affinity maturation of Vitaxin, and $\alpha, \beta_3$ -specific humanized mAb," <i>Proc. Natl. Acad. Sci. USA</i> , 95:6037-6042 (1998)			
	64	Yelton <i>et al.</i> , "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," <i>J Immunol</i> 155:1994-2004 (1995)			
	65				
	66				
	67				
	68				
	69				
	70				
	71				
	72				
	73				
	74				
	75				
	76				
	77				
	78				
	79				
	80				
Examiner:			Date Considered:		
<b>EXAMINER:</b> Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					